Hossein Ayatollahi - Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Ali Bazi - Clinical Research Development Unit, Amir-Al-Momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran
Mohammad Hadi Sadeghian - Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Ali Fani - Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Background & Objective: Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) is a relatively common subtype of acute myeloid leukemia (AML).  Here, our objective was to ascertain the survival of patients with this leukemia in north-east of Iran. Methods: Survival rates of 42 APL patients with t(15;17)(q22;q12) were assessed. Clinical information was obtained from archived medical records. Statistical analysis was performed by SPSS 18 software using log-ranked test and Kaplan Maier survival analysis. Results: Females and males comprised 49% and 51%, respectively. The mean age at diagnosis was 34.3 14.1 years old. During the study period, 17 demises occurred in males, while this number was 7 in females. The mean survival of patients (month) was 23.22 3.57 (95% CI: 16.21 30.2).  The five-year survival rate obtained 30%. Regarding demographic and clinical features, the highest rates of 5-year survival were recorded in patients with 20-35 years old (47.6%), males (51%), white blood cell count 140 /l (100%). Conclusion: Younger age, lower WBC count and higher platelet count were significantly associated with longer survival in AML patients with t(15;17)(q22; q12).

Acute myeloid leukemia, Acute promyelocytic leukemia, Blood cancer, Survival, t(15, 17)(q22, q12)